Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide

JY Hor, N Asgari, I Nakashima, SA Broadley… - Frontiers in …, 2020 - frontiersin.org
Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease of
the central nervous system, manifesting clinically as optic neuritis, myelitis, and certain brain …

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)–revised recommendations of the Neuromyelitis Optica Study Group …

S Jarius, O Aktas, I Ayzenberg, J Bellmann-Strobl… - Journal of …, 2023 - Springer
The term 'neuromyelitis optica spectrum disorders'(NMOSD) is used as an umbrella term that
refers to aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica (NMO) …

Health disparities, inequities, and social determinants of health in multiple sclerosis and related disorders in the US: a review

L Amezcua, VM Rivera, TC Vazquez… - JAMA …, 2021 - jamanetwork.com
Importance There is empirical evidence that social determinants of health (SDOH) impact
health outcomes in Black and Hispanic and Latinx individuals in the US. Recently, SDOH …

[HTML][HTML] Neuromyelitis optica spectrum disorders

S Huda, D Whittam, M Bhojak, J Chamberlain… - Clinical Medicine, 2019 - Elsevier
Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon antibody-mediated
disease of the central nervous system. Long segments of spinal cord inflammation (myelitis) …

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology

K Fujihara, JL Bennett, J de Seze… - Neurology …, 2020 - AAN Enterprises
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disorder that
preferentially affects the spinal cord and optic nerve. Most patients with NMOSD experience …

Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis

N Borisow, M Mori, S Kuwabara, M Scheel… - Frontiers in …, 2018 - frontiersin.org
Neuromyelitis optica spectrum disorders (NMOSD) are autoantibody mediated chronic
inflammatory diseases. Serum antibodies (Abs) against the aquaporin-4 water channel lead …

Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease

P Barreras, ES Vasileiou, AG Filippatou, KC Fitzgerald… - Neurology, 2022 - AAN Enterprises
Background and Objectives Rituximab is used widely for relapse prevention in neuromyelitis
optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein (MOG)-IgG …

AQP4-IgG and MOG-IgG related optic neuritis—prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis

AG Filippatou, L Mukharesh, S Saidha… - Frontiers in …, 2020 - frontiersin.org
Background: Optic neuritis (ON) is a cardinal manifestation of multiple sclerosis (MS),
aquaporin-4 (AQP4)-IgG-, and myelin oligodendrocyte glycoprotein (MOG)-IgG-associated …

Inebilizumab: first approval

JE Frampton - Drugs, 2020 - Springer
Inebilizumab (Uplizna™; inebilizumab-cdon in the USA) is a humanised anti-CD19
monoclonal antibody being developed by Viela Bio for the treatment of a range of …

Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice

EC Contentti, JI Rojas, E Cristiano, VD Marques… - Multiple sclerosis and …, 2020 - Elsevier
Background During the last two decades, neuromyelitis optica spectrum disorder (NMOSD)
has undergone important changes, with new diagnostic markers and criteria, better …